This week PharmaShots’ news was all about the updates on Clinical Trials, Regulatory, Pharma, MedTech, M&A, Animal Health & Biosimilars. Check out our full report below: 

Eli Lilly Reveals VIVID-2 Study Data of Omvoh to Treat Crohn's Disease 

Read More: Eli Lilly 

Regeneron Reveals Data from Extended P-III (PULSAR) Trial of Eylea HD for Wet Age-related Macular Degeneration 

Read More: Regeneron 

BMS Reports Topline Data from P-II (TRANSCEND FL) trial of Breyanzi for R/R Indolent B-cell non-Hodgkin lymphoma 

Read More: BMS 

Boehringer Ingelheim Reports Topline Data from P-III (FIBRONEER-ILD) Study of Nerandomilast for Progressive Pulmonary Fibrosis (PPF) 

Read More: Boehringer Ingelheim 

Pfizer and Astellas Report Follow-up Data from P-III (KEYNOTE-A39/EV-302) Trial of Padcev + Keytruda for Locally Advanced or Metastatic Urothelial Cancer (la/mUC) 

Read More: Pfizer and Astellas 

Pfizer Reports Data from P-III (TALAPRO-2) Trial of Talzenna + Xtandi for Metastatic Castration Resistant Prostate Cancer (mCRPC) 

Read More: Pfizer 

Sanofi and J&J Discontinue P-III (E.mbrace) Study of ExPEC9V for Invasive E. coli Diseases 

Read more: Sanofi and J&J 

Abbvie Reports the US FDA Approval for Emblaveo to Treat Complicated Intra-Abdominal Infections (cIAI) 

Read More: AbbVie 

LIB Therapeutics Reports the US FDA’s BLA Acceptance for Lerodalcibep to Reduce LDL-Cholesterol in Cardiovascular Patients 

Read More: LIB Therapeutics 

Regeneron Reports US FDA’s Acceptance of Resubmitted BLA for Linvoseltamab to Treat R/R Multiple Myeloma (MM) 

Read More: Regeneron 

SpringWorks Therapeutics Receives US FDA Approval for Gomekli to Treat Neurofibromatosis Type 1 Associated Symptomatic Plexiform Neurofibromas (NF1-PN) 

Read More: SpringWorks Therapeutics 

BridgeBio’s Beyonttra (Acoramidis) Gets the EU approval to Treat Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) 

Read More: BridgeBio 

Pfizer Reports the US FDA Approval of Adcetris Regimen to Treat R/R Diffuse Large B-Cell Lymphoma (DLBCL) 

Read More: Pfizer  

CSL Behring Receives the EC Approval for Andembry as a Prophylactic Treatment of HAE 

Read More: CSL Behring  

Bayer Submits MAA of Finerenone to Japan’s MHLW for Heart Failure (HF) 

Read More: Bayer 

Galderma’s Nemluvio (Nemolizumab) Secures the EU Approval to Treat Moderate-To-Severe Atopic Dermatitis (AD) and Prurigo nodularis (PN)

Read More: Galderma

Eli Lilly Acquires OLX75016 from OliX Pharmaceuticals for Metabolic-Associated Steatohepatitis 

Read More: Eli Lilly 

Alloy Therapeutics Enters into a Multi-Year Strategic Collaboration with Pfizer to Develop New Antibody Discovery Platform 

Read More: Alloy Therapeutics and Pfizer 

AbbVie Collaborates with Xilio Therapeutics to Develop Next-Generation Tumor-Activated Immunotherapies 

Read More: AbbVie and Xilio Therapeutics 

Royalty Pharma Partners with Biogen to Develop Litifilimab 

Read More: Royalty Pharma and Biogen 

IDEAYA Enters Into an Additional Clinical Study Collaboration and Supply Agreement with Gilead Sciences 

Read More: IDEAYA and Gilead Sciences

AliveDx Seeks US FDA’s 510(k) Clearance for MosaiQ AiPlex Multiplex Microarray 

Read More: AliveDx 

Ibex Medical Analytics Receives the US FDA’s 510(k) Clearance for Ibex Prostate Detect 

Read More: Ibex Medical Analytics 

Johnson & Johnson MedTech Launches Cereglide 92 Catheter System in the US for Acute Ischemic Stroke 

Read More: Johnson & Johnson 

Novartis to Acquire Anthos Therapeutics for ~$3.1B 

Read More: Novartis and Anthos Therapeutics 

Dalan Animal Health Unlocks the Potential of Innate Immunity with its Vaccine Platform 

Read More: Dalan Animal Health 

Boehringer Ingelheim Launches Semintra in the EU to Treat Feline Hypertension 

Read More: Boehringer Ingelheim 

Bio-Thera Reports the EMA’s MAA Acceptance of BAT2506 (Biosimilar, Simponi) 

Read More: Bio-Thera 

Dr. Reddy’s Partners with Henlius to Commercialize HLX15 (Biosimilar, Darzalex & Darzalex Faspro) in the US & EU 

Read More: Dr. Reddy’s and Henlius 

Celltrion Secures the US FDA’s Approval for Avtozma IV/SC (Biosimilar, Actemra) 

Read More: Celltrion 

Related Post: PharmaShots Weekly Snapshots (February 3rd, 2025 – February 7th, 2025)